ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 35870429

FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.

Lu M and 6 others. Cell Immunol, 2022. Cited by 17 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma. Papers, record 35870429. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35870429

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.
PubMed
Journal
Cell Immunol
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
1.04
iCite
Revised in PubMed
2022-09-21
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lu MMin
2Wang KKaixuan
3Ji WWenxiang
4Yu YYongfeng
5Li ZZiming
6Xia WWeiliang
7Lu SShun

Source PubMed

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Carcinoma, Squamous CellMajor topic
Lung NeoplasmsMajor topic
Receptor, Fibroblast Growth Factor, Type 1Major topic
Animals
B7-H1 Antigen
Cell Line, Tumor
Humans
Jurkat Cells
Lung
Mice
Mice, Inbred C57BL
Programmed Cell Death 1 Receptor
Tumor Escape
Tumor Microenvironment
Up-Regulation

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
42,579,020M2 macrophage-derived exosomal EHF transcriptionally activates FGFR1 to promote malignant phenotypes and glycolysis in NSCLC.J Bioenerg Biomembr2026https://conductscience.org/library/papers/42579020PubMed
42,060,013Unveiling the Intricate Dance: Signaling Pathways in Liver Cancer Metabolism and Immunity.Curr Oncol Rep2026https://conductscience.org/library/papers/42060013PubMed
41,158,313Role of signaling pathways in lung cancer development and advances in targeted therapies (Review).Oncol Lett2025https://conductscience.org/library/papers/41158313PubMed
40,547,805Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy.Explor Target Antitumor Ther2025https://conductscience.org/library/papers/40547805PubMed
40,362,630Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?Int J Mol Sci2025https://conductscience.org/library/papers/40362630PubMed
39,590,377Pharmacological and Biological Targeting of FGFR1 in Cancer.Curr Issues Mol Biol2024https://conductscience.org/library/papers/39590377PubMed
39,567,716Spatial multiomic landscape of the human placenta at molecular resolution.Nat Med2024https://conductscience.org/library/papers/39567716PubMed
37,890,888FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report.J Immunother Cancer2023https://conductscience.org/library/papers/37890888PubMed
37,828,033Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study.Signal Transduct Target Ther2023https://conductscience.org/library/papers/37828033PubMed
37,768,887FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation.Cancer Res2023https://conductscience.org/library/papers/37768887PubMed

1 to 10 of 13

See all 13 cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
FGFR12,260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
PDCD15,133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
YAP110,413PubTator's text mininghttps://conductscience.org/library/genes/10413NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35870429

GET https://conductscience.org/api/papers/v1/35870429/authors

API referenceFor AI assistants